FDA Approves Amivantamab First-line Indication for NSCLC FDA Approves Amivantamab First-line Indication for NSCLC

Amivantamab plus carboplatin and pemetrexed is now available for first-line treatment of locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology Source Type: news